Neonc Technologies Holdings Inc NTHI

$12.00 -0.11 (-0.91%)

Valuation

Market cap: —
Revenue TTM: —
Net income TTM: —
PE ratio: —
Forward PE: —
Profit margin: —
Debt to equity: —

Trading

Volume: 9,700
Avg volume: —
Day's range: $10.88 – $14.00
Shares out: —
Stochastic %K: —
Beta: —
Analysts: —
Price target: —

Price

Company profile

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 310 663 7831
Website: https://www.neonc.com
Address: 23975 Park Sorrento, Suite 205, Calabasas, United States

Latest news

No headlines yet.

Stocktwits

NVDAMillionaire Oct 2, 11:26 PM

$NTHI Outstanding article that hits the mark on NTHI's current state. So if you want to refresh your NTHI insights or learn about NTHI from scratch, this is a must read. https://everyticker.com/quote/NTHI/analysis/neonc-s-5-stock-a-135m-deficit-vs-48-9-survival-signal-in-brain-cancer-nasdaq-nthi

0 replies

Tariqlati Oct 2, 2:30 PM

$NTHI easy $20 $IOVA $RXRX

0 replies

NeOnc_Technologies Oct 2, 2:16 PM

NEO212 enters its next regulatory milestone with Phase 1 dose escalation completed and 610 mg selected as the recommended Phase 2 dose. Clinical observations reported to date include approximately 60% tumor reduction followed by 21 months of disease control in one recurrent GBM patient, and approximately 16 months of stable disease in a patient with brain metastases. While individual cases do not establish efficacy, these observations provide important clinical context as we prepare for the November 17 FDA meeting and the next stage of NEO212’s development. $NTHI $NVAX $RXRX

0 replies

OldToad77 Oct 1, 11:35 AM

$NTHI Took a position

0 replies

Tariqlati Oct 1, 11:18 AM

$NTHI just a matter of time and it will boom $IOVA

0 replies

Tariqlati Oct 1, 9:28 AM

$NTHI NeOnc NEO212 FDA Meeting Set for Nov. 17 | NTHI Stock News https://share.google/e9WAW9cDoEh1iJxde

0 replies

NeOnc_Technologies Sep 30, 2:35 PM

November 17 marks the next regulatory milestone for $NTHI. Following completion of NEO212 Phase 1 dose escalation and selection of 610 mg as the recommended Phase 2 dose, we have scheduled an in-person End-of-Phase 1 Type B Meeting with the FDA. The meeting will focus on patient population, trial design, endpoints and the evidence needed to support NEO212’s next stage of development, while also seeking FDA feedback on a potential registrational strategy and accelerated approval pathway. $NTHI $VKTX $MRNA

0 replies

MarketDegenerate Sep 29, 6:31 AM

$NTHI — NeOnc has several things happening at once. NEO100 produced positive Phase 2a results in recurrent malignant glioma, management recently raised $15M, and the company has now scheduled an FDA End-of-Phase 1 meeting for NEO212. That FDA discussion should help determine the next clinical-development steps

0 replies